-
2
-
-
0035989794
-
Cardiovascular disease risk factors in chronic renal insufficiency
-
Sarnak MJ, Coronado BE, Greene T, Wang SR, Kusek JW, Beck GJ, Levey AS: Cardiovascular disease risk factors in chronic renal insufficiency. Clin Nephrol 57: 327-335, 2002
-
(2002)
Clin Nephrol
, vol.57
, pp. 327-335
-
-
Sarnak, M.J.1
Coronado, B.E.2
Greene, T.3
Wang, S.R.4
Kusek, J.W.5
Beck, G.J.6
Levey, A.S.7
-
3
-
-
0042073221
-
Traditional cardiac risk factors in individuals with chronic kidney disease
-
Uhlig K, Levey AS, Sarnak MJ: Traditional cardiac risk factors in individuals with chronic kidney disease. SeminDial 16: 118-127, 2003
-
(2003)
SeminDial
, vol.16
, pp. 118-127
-
-
Uhlig, K.1
Levey, A.S.2
Sarnak, M.J.3
-
4
-
-
63849163945
-
Rosuvastatin and cardiovascular events in patients undergoing hemodialysis
-
AURORA Study Group
-
Fellström BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, Chae DW, Chevaile A, Cobbe SM, Grönhagen-Riska C, De Lima JJ, Lins R, Mayer G, McMahon AW, Parving HH, Remuzzi G, Samuelsson O, Sonkodi S, Sci D, Süleymanlar G, Tsakiris D, Tesar V, Todorov V, Wiecek A, Wüthrich RP, Gottlow M, Johnsson E, Zannad F; AURORA Study Group: Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 360: 1395-1407, 2009
-
(2009)
N Engl J Med
, vol.360
, pp. 1395-1407
-
-
Fellström, B.C.1
Jardine, A.G.2
Schmieder, R.E.3
Holdaas, H.4
Bannister, K.5
Beutler, J.6
Chae, D.W.7
Chevaile, A.8
Cobbe, S.M.9
Grönhagen-Riska, C.10
De Lima, J.J.11
Lins, R.12
Mayer, G.13
McMahon, A.W.14
Parving, H.H.15
Remuzzi, G.16
Samuelsson, O.17
Sonkodi, S.18
Sci, D.19
Süleymanlar, G.20
Tsakiris, D.21
Tesar, V.22
Todorov, V.23
Wiecek, A.24
Wüthrich, R.P.25
Gottlow, M.26
Johnsson, E.27
Zannad, F.28
more..
-
5
-
-
78650184434
-
Study of Heart and Renal Protection (SHARP): Randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease
-
Sharp Collaborative G. Study of Heart and Renal Protection (SHARP): Randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. Am Heart J 160: 785-794. 2010
-
(2010)
Am Heart J
, vol.160
, pp. 785-794
-
-
Sharp Collaborative, G.1
-
6
-
-
22344458137
-
Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis
-
German Diabetes and Dialysis Study Investigators
-
Wanner C, Krane V, März W, Olschewski M, Mann JF, Ruf G, Ritz E; German Diabetes and Dialysis Study Investigators: Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl JMed 353: 238-248, 2005
-
(2005)
N Engl JMed
, vol.353
, pp. 238-248
-
-
Wanner, C.1
Krane, V.2
März, W.3
Olschewski, M.4
Mann, J.F.5
Ruf, G.6
Ritz, E.7
-
7
-
-
78449281377
-
Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170,000 participants in 26 randomised trials
-
Cholesterol Treatment Trialists' (CTT) Collaboration
-
Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R; Cholesterol Treatment Trialists' (CTT) Collaboration: Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376: 1670-1681, 2010
-
(2010)
Lancet
, vol.376
, pp. 1670-1681
-
-
Baigent, C.1
Blackwell, L.2
Emberson, J.3
Holland, L.E.4
Reith, C.5
Bhala, N.6
Peto, R.7
Barnes, E.H.8
Keech, A.9
Simes, J.10
Collins, R.11
-
8
-
-
79959746706
-
The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): A randomised placebo-controlled trial
-
SHARP Investigators
-
Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, Wanner C, Krane V, Cass A, Craig J, Neal B, Jiang L, Hooi LS, Levin A, Agodoa L, Gaziano M, Kasiske B, Walker R, Massy ZA, Feldt-Rasmussen B, Krairittichai U, Ophascharoensuk V, Fellström B, Holdaas H, Tesar V, Wiecek A, Grobbee D, de Zeeuw D, Grönhagen-Riska C, Dasgupta T, Lewis D, Herrington W, Mafham M, Majoni W, Wallendszus K, Grimm R, Pedersen T, Tobert J, Armitage J, Baxter A, Bray C, Chen Y, Chen Z, Hill M, Knott C, Parish S, Simpson D, Sleight P, Young A, Collins R; SHARP Investigators: The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): A randomised placebo-controlled trial. Lancet 377: 2181-2192, 2011
-
(2011)
Lancet
, vol.377
, pp. 2181-2192
-
-
Baigent, C.1
Landray, M.J.2
Reith, C.3
Emberson, J.4
Wheeler, D.C.5
Tomson, C.6
Wanner, C.7
Krane, V.8
Cass, A.9
Craig, J.10
Neal, B.11
Jiang, L.12
Hooi, L.S.13
Levin, A.14
Agodoa, L.15
Gaziano, M.16
Kasiske, B.17
Walker, R.18
Massy, Z.A.19
Feldt-Rasmussen, B.20
Krairittichai, U.21
Ophascharoensuk, V.22
Fellström, B.23
Holdaas, H.24
Tesar, V.25
Wiecek, A.26
Grobbee, D.27
de Zeeuw, D.28
Grönhagen-Riska, C.29
Dasgupta, T.30
Lewis, D.31
Herrington, W.32
Mafham, M.33
Majoni, W.34
Wallendszus, K.35
Grimm, R.36
Pedersen, T.37
Tobert, J.38
Armitage, J.39
Baxter, A.40
Bray, C.41
Chen, Y.42
Chen, Z.43
Hill, M.44
Knott, C.45
Parish, S.46
Simpson, D.47
Sleight, P.48
Young, A.49
Collins, R.50
more..
-
9
-
-
0025156823
-
Serum plant sterols and cholesterol precursors reflect cholesterol absorption and synthesis in volunteers of a randomly selectedmale population
-
Miettinen TA, Tilvis RS, Kesäniemi YA: Serum plant sterols and cholesterol precursors reflect cholesterol absorption and synthesis in volunteers of a randomly selectedmale population. AmJ Epidemiol 131: 20-31, 1990
-
(1990)
AmJ Epidemiol
, vol.131
, pp. 20-31
-
-
Miettinen, T.A.1
Tilvis, R.S.2
Kesäniemi, Y.A.3
-
10
-
-
0032507494
-
Baseline serum cholestanol as predictor of recurrent coronary events in subgroup of Scandinavian simvastatin survival study. Finnish 4S Investigators
-
Miettinen TA, Gylling H, Strandberg T, Sarna S: Baseline serum cholestanol as predictor of recurrent coronary events in subgroup of Scandinavian simvastatin survival study. Finnish 4S Investigators. BMJ 316: 1127-1130, 1998
-
(1998)
BMJ
, vol.316
, pp. 1127-1130
-
-
Miettinen, T.A.1
Gylling, H.2
Strandberg, T.3
Sarna, S.4
-
11
-
-
30044443681
-
Cholestanol: A serum marker to guide LDL cholesterol-lowering therapy
-
Hoenig MR, Rolfe BE, Campbell JH: Cholestanol: A serum marker to guide LDL cholesterol-lowering therapy. Atherosclerosis 184: 247-254, 2006
-
(2006)
Atherosclerosis
, vol.184
, pp. 247-254
-
-
Hoenig, M.R.1
Rolfe, B.E.2
Campbell, J.H.3
-
12
-
-
77953271764
-
Alterations of cholesterol precursor levels in Alzheimer's disease
-
Kölsch H, Heun R, Jessen F, Popp J, Hentschel F, Maier W, Lütjohann D: Alterations of cholesterol precursor levels in Alzheimer's disease. Biochim Biophys Acta 1801: 945-950, 2010
-
(2010)
Biochim Biophys Acta
, vol.1801
, pp. 945-950
-
-
Kölsch, H.1
Heun, R.2
Jessen, F.3
Popp, J.4
Hentschel, F.5
Maier, W.6
Lütjohann, D.7
-
13
-
-
0242721947
-
Synthesis and absorption markers of cholesterol in serum and lipoproteins during a large dose of statin treatment
-
Miettinen TA, Gylling H: Synthesis and absorption markers of cholesterol in serum and lipoproteins during a large dose of statin treatment. Eur J Clin Invest 33: 976-982, 2003
-
(2003)
Eur J Clin Invest
, vol.33
, pp. 976-982
-
-
Miettinen, T.A.1
Gylling, H.2
-
14
-
-
67449123465
-
Comparison of the effects of maximal dose atorvastatin and rosuvastatin therapy on cholesterol synthesis and absorption markers
-
van Himbergen TM, Matthan NR, Resteghini NA, Otokozawa S, Ai M, Stein EA, Jones PH, Schaefer EJ:Comparison of the effects of maximal dose atorvastatin and rosuvastatin therapy on cholesterol synthesis and absorption markers. J Lipid Res 50: 730-739, 2009
-
(2009)
J Lipid Res
, vol.50
, pp. 730-739
-
-
van Himbergen, T.M.1
Matthan, N.R.2
Resteghini, N.A.3
Otokozawa, S.4
Ai, M.5
Stein, E.A.6
Jones, P.H.7
Schaefer, E.J.8
-
15
-
-
77953229699
-
Relationship between cholesterol synthesis and intestinal absorption is associated with cardiovascular risk
-
Weingärtner O, Lütjohann D, Böhm M, Laufs U: Relationship between cholesterol synthesis and intestinal absorption is associated with cardiovascular risk. Atherosclerosis 210: 362-365, 2010
-
(2010)
Atherosclerosis
, vol.210
, pp. 362-365
-
-
Weingärtner, O.1
Lütjohann, D.2
Böhm, M.3
Laufs, U.4
-
16
-
-
33644854296
-
Dyslipidemia of chronic renal failure: The nature, mechanisms, and potential consequences
-
Vaziri ND: Dyslipidemia of chronic renal failure: The nature, mechanisms, and potential consequences. Am J Physiol Renal Physiol 290: F262-F272, 2006
-
(2006)
Am J Physiol Renal Physiol
, vol.290
-
-
Vaziri, N.D.1
-
17
-
-
1642527950
-
Cholesterol metabolism in patients with chronic renal failure on hemodialysis
-
Igel-Korcagova A, Raab P, Brensing KA, Pöge U, Klehr HU, Igel M, von Bergmann K, Sudhop T: Cholesterol metabolism in patients with chronic renal failure on hemodialysis. J Nephrol 16: 850-854, 2003
-
(2003)
J Nephrol
, vol.16
, pp. 850-854
-
-
Igel-Korcagova, A.1
Raab, P.2
Brensing, K.A.3
Pöge, U.4
Klehr, H.U.5
Igel, M.6
von Bergmann, K.7
Sudhop, T.8
|